Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA)

CAPS Rating: 5 out of 5

A global pharmaceutical company, Teva develops, produces, and markets generic drugs covering all major treatment categories.

Results 1 - 20 of 390 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar john603 (59.38) Submitted: 8/31/2014 10:45:57 PM : Outperform Start Price: $52.09 TEVA Score: +8.57

generic drugs. dividends.

Recs

1
Member Avatar thecashmen (22.25) Submitted: 6/2/2014 6:20:06 PM : Outperform Start Price: $51.34 TEVA Score: +5.63

I work in a pharmacy and teva sell the most drugs by far. I look at their numbers and they are solid but who cares about the numbers when I see with my own two eyes that their product sell by the truckload

Recs

0
Member Avatar TerryFool (55.34) Submitted: 6/1/2014 7:53:32 PM : Outperform Start Price: $50.17 TEVA Score: +8.57

2015 EPS 4.77, PE est 10.6

Recs

0
Member Avatar afewgoodstocks11 (25.35) Submitted: 5/16/2014 5:29:19 PM : Outperform Start Price: $37.03 TEVA Score: +30.97

Div. (Yield) $1.18 (2.3%)
Current Yield . . . . . . 3.5%

Recs

0
Member Avatar SnowBawl (< 20) Submitted: 5/15/2014 7:57:08 AM : Outperform Start Price: $49.26 TEVA Score: +8.29

4 Big Elderly. Reeves.

Recs

0
Member Avatar BTE78 (41.49) Submitted: 4/24/2014 2:02:39 AM : Outperform Start Price: $49.64 TEVA Score: +7.13

It's one of these stocks that's worth a gamble and one that I'm willing to play on for the long haul.

Recs

0
Member Avatar InvestmentMAGE (< 20) Submitted: 3/22/2014 3:06:06 PM : Outperform Start Price: $48.83 TEVA Score: +8.23

John Neff Screen

Recs

0
Member Avatar DrGarnicus (39.57) Submitted: 3/11/2014 2:53:29 PM : Outperform Start Price: $48.73 TEVA Score: +8.64

Many new possibilities on the horizon.

Recs

0
Member Avatar stemcells2011 (88.39) Submitted: 2/21/2014 4:56:04 PM : Outperform Start Price: $41.05 TEVA Score: +28.87

This company is tremendously undervalued. They have a good-sized market share of generic drugs in the US (that are going up in price) and expanding their brand patents. Will likely see $60 in one year as the sector continues to rise on what I perceive to be a realization that drugs are more valuable than gold.

Recs

0
Member Avatar gcswim54 (< 20) Submitted: 2/21/2014 2:08:16 AM : Outperform Start Price: $47.61 TEVA Score: +9.88

George Soros is increasing his market share here. Also it is hitting a good timing period in several generic patent expiration's. Should be a good hold for a year or so.

Recs

0
Member Avatar grahamfordummies (71.89) Submitted: 12/2/2013 5:21:13 PM : Outperform Start Price: $39.77 TEVA Score: +31.06

Copaxone (daily injection to treat Multiple Sclerosis) is facing branded and potential generic competition and is roughly 60% of current profits, the CEO just resigned and pipeline visibility is low.
So why buy it here? IY is too cheap. While all of these negatives are well known and fully baked in, there are multiple potential positives that are noy well understood. They include a broad respiratory pipeline that is starting to get increased disclosure, a broad portfolio of NTE's (new therapeutic entities) that will be more fully disclosed in a Teva Webinar on December 5th, The Proctor and Gamble JV (PGT) that sells PG's OTC products in the emerging markets, a still industry leading first to file (FTF) line up of abbreviated new drud applications (ANDA's) combines with a new generic patent expiration cycle starting in 2015 and a stabilizing European market place. All of this at 8x the 2013 comsensus. Buy.

Recs

0
Member Avatar EruditeInvestor (51.18) Submitted: 11/19/2013 7:52:45 PM : Outperform Start Price: $39.17 TEVA Score: +32.93

Teva Pharmaceutical is the only stock (a total of 50 companies) selling below its forecasted range ( $47.81 to $67.28) of my proprietary QVT Equity Valuation System. Its current dividend of $1.11 yields 2.9%. TEVA has ususally increased its dividend annually and is in Powersshares International Dividend Achievers ETF (Symbol: PID). The company is one of the largest manufacturerers of generic medicines.

Recs

0
Member Avatar stockdoc00 (< 20) Submitted: 11/18/2013 9:34:56 PM : Outperform Start Price: $37.42 TEVA Score: +39.82

Strong company in both the generic drug market as well as having strong stable of branded drugs, particularly in the neurosciences. One of the better values at this current price among the large pharmaceuticals.

Recs

0
Member Avatar clangmu2 (< 20) Submitted: 10/16/2013 7:28:28 PM : Outperform Start Price: $38.71 TEVA Score: +29.34

Strong and steady growth in revenue and book value with very low P//E. Good dividend yield provides a good floor to the present price. Substantial price appreciate seems reasonable.

Recs

0
Member Avatar rossnr3 (43.54) Submitted: 6/4/2013 9:33:39 AM : Outperform Start Price: $36.95 TEVA Score: +31.69

Loss of patent protection around 2015 that provides 50% of profit.

Recs

0
Member Avatar shuli100 (< 20) Submitted: 5/10/2013 7:22:38 AM : Outperform Start Price: $37.18 TEVA Score: +29.31

A good stock

Recs

0
Member Avatar elnidodelaguila (29.43) Submitted: 4/25/2013 7:35:49 AM : Outperform Start Price: $37.01 TEVA Score: +26.27

Hight quality Generic drugs will be adopted by most of healthcare systems to improve their patients covering on low cost..

Recs

0
Member Avatar PrototypeZ (26.83) Submitted: 4/12/2013 9:12:49 AM : Underperform Start Price: $37.22 TEVA Score: -29.12

Patent cliff

Recs

0
Member Avatar robotclo (70.05) Submitted: 3/18/2013 5:25:03 AM : Outperform Start Price: $38.52 TEVA Score: +16.78

Patent cliffs. So many patent cliffs.

Recs

0
Member Avatar JorgeAura (< 20) Submitted: 2/2/2013 5:36:20 PM : Underperform Start Price: $35.72 TEVA Score: -24.98

Nasdaq in maximums.

Featured Broker Partners


Advertisement